Polypharmacy and Kidney Function in Community-Dwelling Adults Age 60 Years and Older: A Prospective Observational Study by Ernst, Rahel et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Polypharmacy and Kidney Function in Community-Dwelling Adults Age 60
Years and Older: A Prospective Observational Study
Ernst, Rahel ; Fischer, Karina ; de Godoi Rezende Costa Molino, Caroline ; Orav, Endel J ; Theiler,
Robert ; Meyer, Ursina ; Fischler, Manuel ; Gagesch, Michael ; Ambühl, Patrice M ; Freystätter, Gregor
; Egli, Andreas ; Bischoff-Ferrari, Heike A
Abstract: Objectives Information on the impact of polypharmacy on kidney function in older adults
is limited. We prospectively investigated the association between intake of total number of drugs or
nonsteroidal anti-inflammatory drugs (NSAIDs) and kidney function. Design Our study is a prospective
observational analysis of the 2-year Zurich Multiple Endpoint Vitamin D Trial in Knee Osteoarthritis
Patients. Setting and participants Of the 273 participants of the original trial, 270 participants (mean age
70.3 ± 6.4 years, 53% women) were included in this observational analysis. Methods The associations
between (1) total number of drugs (or NSAIDs) at baseline or (2) cumulative number of drugs (or
NASAIDs) repeatedly measured over 24 months and kidney function repeatedly measured over 24 months
as estimated glomerular filtration rate (eGFR) were investigated using multivariable-adjusted repeated-
measures analysis. Results Per drug at baseline, kidney function decreased by 0.64 mL/min/1.73 m2
eGFR (Beta = −0.64; 95% CI −1.19 to −0.08; P = .024) over 24 months. With every additional drug
taken cumulatively over 24 months, kidney function decreased by 0.39 mL/min/1.73 m2 eGFR (Beta =
−0.39; 95% CI −0.63 to −0.15; P = .002). In a high-risk subgroup, per NSAID taken cumulatively over
24 months, kidney function declined by 1.21 mL/min/1.73 m2 eGFR (Beta = −1.21; 95% CI −2.35 to
−0.07; P = .021). Conclusions and implications For every additional drug prescribed among older adults,
our study supports an independent and immediate harmful impact on kidney function. This negative
impact seems to be about 3 times greater for NSAIDs compared with an additional average drug.
DOI: https://doi.org/10.1016/j.jamda.2019.07.007
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-177308
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Ernst, Rahel; Fischer, Karina; de Godoi Rezende Costa Molino, Caroline; Orav, Endel J; Theiler, Robert;
Meyer, Ursina; Fischler, Manuel; Gagesch, Michael; Ambühl, Patrice M; Freystätter, Gregor; Egli, An-
dreas; Bischoff-Ferrari, Heike A (2019). Polypharmacy and Kidney Function in Community-Dwelling
Adults Age 60 Years and Older: A Prospective Observational Study. Journal of the American Medical
Directors Association:Epub ahead of print.
DOI: https://doi.org/10.1016/j.jamda.2019.07.007
2
Original Study
Polypharmacy and Kidney Function in Community-Dwelling Adults
Age 60 Years and Older: A Prospective Observational Study
Rahel Ernst MD a,b,c,y, Karina Fischer PhD a,b,y,
Caroline de Godoi Rezende Costa Molino MSc a,b, Endel J. Orav PhD d,
Robert Theiler MD a,b, Ursina Meyer PhD a,b, Manuel Fischler MD c,
Michael Gagesch MDa,b, Patrice M. Ambühl MD e, Gregor Freystätter MD a,b,
Andreas Egli MD a,b, Heike A. Bischoff-Ferrari MD, DrPH a,b,f,*
aDepartment of Geriatrics and Aging Research, University Hospital Zurich, University of Zurich, Zurich, Switzerland
bCenter on Aging and Mobility, University Hospital Zurich, City Hospital Waid Zurich, Zurich, Switzerland
c Internal Medicine Clinic, City Hospital Waid, Zurich, Switzerland
dDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA
e Institute of Nephrology, City Hospital Waid, Zurich, Switzerland
fUniversity Clinic for Acute Geriatric Care, City Hospital Waid, Zurich, Switzerland
Keywords:
Polypharmacy
kidney function
eGFR
older adults
nonsteroidal anti-inﬂammatory drugs
(NSAIDS)
cumulative drug intake
prospective analysis
a b s t r a c t
Objectives: Information on the impact of polypharmacy on kidney function in older adults is limited. We
prospectively investigated the association between intake of total number of drugs or nonsteroidal anti-
inﬂammatory drugs (NSAIDs) and kidney function.
Design: Our study is a prospective observational analysis of the 2-year Zurich Multiple Endpoint Vitamin
D Trial in Knee Osteoarthritis Patients.
Setting and participants: Of the 273 participants of the original trial, 270 participants (mean age
70.3  6.4 years, 53% women) were included in this observational analysis.
Methods: The associations between (1) total number of drugs (or NSAIDs) at baseline or (2) cumulative
number of drugs (or NASAIDs) repeatedly measured over 24 months and kidney function repeatedly
measured over 24 months as estimated glomerular ﬁltration rate (eGFR) were investigated using
multivariable-adjusted repeated-measures analysis.
Results: Per drug at baseline, kidney function decreased by 0.64 mL/min/1.73 m2 eGFR (Beta ¼ 0.64; 95%
CI 1.19 to 0.08; P ¼ .024) over 24 months. With every additional drug taken cumulatively over
24 months, kidney function decreased by 0.39 mL/min/1.73 m2 eGFR (Beta ¼ 0.39; 95% CI 0.63 to
0.15; P ¼ .002). In a high-risk subgroup, per NSAID taken cumulatively over 24 months, kidney function
declined by 1.21 mL/min/1.73 m2 eGFR (Beta ¼ 1.21; 95% CI 2.35 to 0.07; P ¼ .021).
Conclusions and implications: For every additional drug prescribed among older adults, our study sup-
ports an independent and immediate harmful impact on kidney function. This negative impact seems to
be about 3 times greater for NSAIDs compared with an additional average drug.
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The population segment of adults age 65 years and older is
growing rapidly to an expected 30% in 2050.1,2 Inevitably, this de-
mographic change will be associated with an increase in the number
of age-related chronic diseases treated with a rising number of drugs.3
Polypharmacy among the growing segment of older patients raises
concerns about limited data on how common drugs individually and
in combination affect kidney function in older adults, as this segment
of the population has been largely excluded from clinical trials.4
Notably, the percentage of adults aged 65 years or older taking 5 or
more drugs has doubled from 20% in 1995 to almost 40% in 2010.3 In
the same time period, the incidence of chronic kidney disease (CKD)
has also more than doubled in this age group.5 Age alonewill decrease
the glomerular ﬁltration rate (GFR) by about 0.8 to 1 mL/min/1.73 m2/
year over the age of 40 years.68 And age-related chronic diseases such
as hypertension,9 diabetes,10 and obesity11 have been shown to
negatively impact kidney function independent of age.11
In addition, several drugs, such as nonsteroidal anti-inﬂammatory
drugs (NSAIDs),12,13 virostatics,14 calcineurin inhibitors,15 and
bisphosphonates,14 have been identiﬁed as high-risk drugs, especially
if kidney function is already impaired due to prevalent age-related
chronic diseases.16,17 However, although the association between
reduced kidney function and the risk of mortality, cardiovascular
events, and rate of hospitalization is well established,18 only limited
data is available on how polypharmacy affects kidney function pro-
spectively and cumulatively among community-dwelling adults aged
60 years and older.17
Therefore, in this study, we investigated the association between
polypharmacy and kidney function prospectively over 2 years with 6
monthly assessments among adults aged 60 years and older, bothwith
regard to baseline and cumulative exposure over time. We also per-
formed a subgroup analysis for NSAIDs as a known high-risk
medication.
Methods
Participants and Study Design
The present study is a secondary observational analysis utilizing
data that was originally collected as part of the Zurich Multiple
Endpoint Vitamin D Trial in Knee Osteoarthritis Patients
(NCT00599807),19 a 2-year single-center double-blind randomized
controlled trial (RCT) investigating the effect of vitamin D (2000 IU/
d vs 800 IU/d cholecalciferol) on pain and disability in patients with
knee osteoarthritis between 2008 and 2014 at the University Hospital
Zurich, Switzerland.
The original RCT enrolled 273 participants aged 60 years and older
(community-dwelling, mean age 70.4 years, 53% women) who were
undergoing elective surgery for unilateral knee replacement because
of severe knee osteoarthritis and were recruited from 2 large hospital
centers (Schulthess Clinic, Zurich; Triemli City Hospital, Zurich).19
Exclusion criteria of the original RCT important for the present
study included history of inﬂammatory arthritis, chronic corticoste-
roid use, hypercalcemia, kidney disease (estimated creatinine clear-
ance by Cockroft-Gault equation <30 mL/min), kidney stone within
10 years, and current cancer.
Throughout the original 2-year trial, participants were invited to
the study center at baseline and every 6 months (at 6, 12, 18, and
24months) for a follow-up visit. At each visit, drug intakewas updated
and kidney function parameters including serum creatinine (sCr),
serum cystatin C (sCys), and urine albuminwere measured. Of the 273
participants enrolled in the original RCT, 270 participants who had
complete information on kidney function and medication intake at
baseline were included in the present observational analysis. Of these
270 participants, data of 259 (96% at 6 months), 254 (94% at
12 months), 243 (90% at 18 months), and 226 (84% at 24 months)
participants were available for the present observational analysis
because of drop outs (n ¼ 44) during the original RCT.19
The original RCT was in accordance with the principles as outlined
in the Declaration of Helsinki of 1975 as revised in 1983, and all par-
ticipants gave their written informed consent to the study, which was
approved by the Cantonal Ethical Commission of Zurich (Protocol
identiﬁer STZ 20/07), Switzerland. The proposal for the present sec-
ondary investigation on the prospective association between poly-
pharmacy and kidney functionwas approved by the Ethics Committee
Zurich (ID 2016-00750).
Assessment of Drug Intake
Self-reported intake of prescribed and over-the-counter drugs was
assessed at each visit (ie, at baseline and 6, 12, 18, and 24 months),
including the brand name, Anatomical Therapeutic Chemical Classi-
ﬁcation (ATC) code,20 ingredients, dose, dosage, indication, and
duration. For the present analysis and to be consistent with the
literature on polypharmacy,21,22 we excluded drugs taken “as needed,”
all herbal medicines, homeopathics, and nutritional supplements. We
included all types of drug applications (ie, oral, topical, nasal, inhaled,
and parenteral).
For each participant, the self-reported total number of different
drugs taken at each timepointwas counted. In addition, based on these
numbers, for each participant the cumulative number of drugs taken at
a speciﬁc visit was calculated as the sum of all drugs taken up to that
visit.We used a cumulative concept of polypharmacy, deﬁning it as the
sumof all different typesof drugshaving adifferentATC code and taken
daily at baseline orwithin 1 of the four 6-month follow-up periods. For
instance, if a participant tookbothparacetamol andpantoprazole daily,
the cumulative intake at baseline was 2. If the participant continued
with the same medication from baseline over the whole 24-month
observational period, the cumulative intake was 10, which is the sum
of 2 drugs counted for the baseline assessment and for each of the four
6-monthperiods (eg, baseline visitþ 6þ12þ18þ 24-month visit).We
did this based on the hypothesis that drug-related nephrotoxicity in-
creases over time when the drug is not withdrawn. So, the cumulative
calculation was performed to take the accumulated drug-related
nephrotoxicity into account.
We used the ATC code to group individual drugs according to
classes and subclasses of drugs.20 The group of NSAIDs included acetic
acid derivatives and related substances (ATC: M01AB0) [ie, oxicams
(M01AC0), propionic acid derivatives (M01AE0)], other anti-
inﬂammatory and antirheumatic agents (nonsteroids) (M01AX0),
coxibs (M01AH0), fenamates (M01AG0), and salicylic acid and de-
rivatives (N02BA0), exclusive of chondroitinsulfat and glucosamine
(M01AX25, M01AX05). Acetylsalicylic acid was only classiﬁed as
NSAID when used as pain killer (500 mg), but not when used for
cardiovascular disease prevention (100 mg).
Assessment of Participant Characteristics and Covariates
Age, sex, diabetes, hypertension, and Charlson comorbidity index
(CCI, score 0‒37)23 were assessed by questionnaire at baseline.Weight
(kg) and height (cm) were measured at baseline. Body mass index
(BMI, in kg/m2) was calculated as weight divided by height squared.
Treatment of the original RCTcompared an oral dose of 2000 IU to 800
IU vitamin D3 per day. Additional assessment of prevalent and inci-
dent comorbidities, hospitalization, frailty criteria, and prevalence of
frailty is described in the online Supplementary Material
(Supplementary Table 1).
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Assessment of Kidney Function
We deﬁned kidney function as the Chronic Kidney Disease Epide-
miology Collaboration creatinine- and cystatin C-based estimated GFR
(CKD-EPIcr-cys eGFR).24,25 Different studies have suggested that the
CKD-EPIcr-cys formula shows the most exact estimated GFR for older
adults in the age range of our study.7,24e26 The CKD-EPIcr-cys eGFR was
calculated by using the age- and sex-related formula deﬁned by Inker
et al.24 Fasting blood samples were taken in the morning when the
participants arrived at the study center. sCys concentration was
determined using a BN100 nephelometer (Dade Behring Inc, Deerﬁeld,
IL) particle-enhanced immunonepholometric assay27 (inter-assay co-
efﬁcient of variation of 5.9% at a level of 1.14 mg/L and 4.8% at a level of
2.18 mg/L). sCr concentration was determined using a kinetic Jaffe
method traceable to isotopedilutionmass spectrometry (IDMS) (Roche
Diagnostics, Rotkreuz, Switzerland) with an inter-assay coefﬁcient of
variationof 2.4% at a level of 95mmol/L and2.3% at a level of 337mmol/L.
sCr, sCys, and CKD-EPIcr-cys eGFR were measured at each visit (ie, at
baseline and 6, 12, 18, and 24 months using collected venous blood).
Statistical Analyses
Statistical analysis was performed using SAS v 9.4 (SAS Institute,
Inc, Cary, NC). Differences in baseline characteristics betweenmen and
women were analyzed using a c2 test for categorical variables and
Student t-test for continuous variables. P value for trend across tertiles
of drug intake was calculated from linear regression models using the
median value of the individual tertiles as a continuous variable. We
analyzed the number of drugs as continuous variables and tertiles
because there is no consensus for the polypharmacy deﬁnition,
particularly in multimorbid older adults.28
As the primary observational analysis, we analyzed the association
of (1) the total number of drugs (as continuous predictor variable) at
baseline or (2) the cumulative intake of drugs (as continuous predictor
variable) at 6, 12, 18, or 24 months with repeated measurements of
kidney function (as continuous response variable) at 6, 12, 18, and
24 months using multivariable-adjusted linear repeated-measures
models with compound-symmetry covariance structure. To account
for possible confounders that may bias the association between drug
intake and kidney function over time because they may also inﬂuence
kidney function, we adjusted our analysis for age, sex, BMI, treatment
groups of the original RCT, prevalence of diabetes, prevalence of hy-
pertension, and the baseline value of the eGFR. To account for the
prevalence of further comorbidities (besides diabetes and hyperten-
sion), we additionally adjusted our models for the baseline CCI,
however, this adjustment did not statistically signiﬁcantly or mean-
ingfully change the results.
Generally, the “Beta” values (unstandardized regression co-
efﬁcients of the multivariable-adjusted models) stated for the
predictor variables (1) baseline or (2) cumulative drug intake in the
results section and Table 1 indicate the impact of an additional
drug taken at baseline or taken cumulatively over 24 months on
kidney function (measured as CKD-EPIcr-cys eGFR [mL/min/
1.73 m2]) after adjusting for confounding covariates [ie, an increase
in drug intake at baseline or in drug intake taken cumulatively
over 24 months by 1 unit (ie, 1 drug) was associated with a change
in the eGFR by the numerical value of “Beta” units (ie, mL/min/
1.73 m2)].
For subgroup analysis on the association between the number of
NSAIDs (as a continuous predictor variable) taken at baseline or the
cumulative number of NSAIDs (as continuous predictor variable)
taken up to the 6-, 12-, 18-, and 24-month follow-up and kidney
function (as continuous response variable) at the 6-, 12-, 18-, and 24-
month follow-up, we used the same multivariable-adjusted linear
repeated-measures models as in the primary analysis.
In addition, we performed a sensitivity analysis to assess the as-
sociation between total number of drug intake (as a continuous
predictor variable) and kidney function (as continuous response
variable) with and without adjusting for the number of RAAS
blockers (ie, angiotensin-converting-enzyme inhibitors and
angiotensin-receptor blockers) in the multivariable-adjusted model
of the primary analysis to account for a possibly biased eGFR
reduction through the mode of action of RAAS blockers, which pre-
serve renal function by lowering intraglomerular pressure, thereby
resulting in a reduction in GFR.29
Statistical signiﬁcance was set at P value of  .05, and reported P
values are 2-sided.
Results
Participant Characteristics
Among the 270 participants included in the present analysis [mean
age 70.3  6.4 years, 53% women, BMI 27.9  4.5 kg/m2, mean CCI
0.5  0.9 (score 0e37); Table 2], the mean intake of drugs at baseline
and the cumulative intake of drugs over 24months were 2.4 2.2 and
14.5  10.5 drugs, respectively. The mean intake of NSAIDs at baseline
and the cumulative intake of NSAIDs over 24 months were 0.17  0.4
and 0.71 1.4 NSAIDs, respectively. The mean eGFR of the total study
sample was 81.6  15.1 mL/min/1.73 m2. Categorized by the “Kidney
Disease: Improving Global Outcomes” (KDIGO) classiﬁcation
(Supplementary Figure 1), participants in the KDIGO GFR G1 (eGFR
90), GFR G2 (eGFR 60‒89), GFR G3a (eGFR 45‒59), and GFR G3b
(eGFR 30‒44) category had mean intakes of 1.92, 2.48, 3.80, and 4.80
drugs at baseline, respectively. Additional information on prevalent
and incident comorbidities, hospitalization, frailty criteria, and prev-
alence of frailty of the participants (Supplementary Table 1) indicates
that besides hypertension, diabetes, and cardiovascular disease, both
Table 1
Prospective Association Between Continuous Values of Baseline or Cumulative Drug Intake and Kidney Function Over 24 mo
Baseline or Cumulative Drug Intake Overall Kidney Function (eGFR) over 24 Mo
Unadjusted Analysis Beta (95% CI) P Adjusted Analysis Beta (95% CI) P
Total drugs
At baseline 2.37 (3.24 to 1.49) .001 0.64 (1.19 to 0.08) .024
Cumulative over 24 mo 0.84 (1.16 to 0.52) <.001 0.39 (0.63 to 0.15) .002
NSAIDs, mean (SD)
At baseline 2.32 (7.20 to 2.56) .47 1.97 (4.51 to 0.59) .26
Cumulative over 24 mo 1.25 (2.70 to 0.10) .09 1.21 (2.35 to 0.07) .021
Data (n¼ 270 at baseline, ie, 0mo; n¼ 259 at 6mo; n¼ 254 at 12mo; n¼ 243 at 18mo, n¼ 226 at 24mo) are unstandardized regression coefﬁcients (Beta) ofmultivariable linear
repeated-measures models unadjusted or adjusted for age, sex, BMI, treatment groups of the original RCT, prevalence of diabetes, prevalence of hypertension, and the baseline
value of the eGFR. Further adjustment for the CCI did not signiﬁcantly change the results. Regression coefﬁcients (Beta) indicate the impact of an additional drug taken at baseline
or taken cumulatively over 24 mo on kidney function (measured as CKD-EPIcr-cys eGFR) (ie, after adjusting for covariates, an increase in drug intake at baseline or in drug intake
taken cumulatively over 24 mo by 1 unit was associated with a change of Beta units in the eGFR). P values are 2-sided; statistical signiﬁcance was set at P < .05.
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the prevalence of other comorbidities at baseline and the incident
comorbidities and hospitalization over time, as well as the prevalence
of frailty over time, were low in our study population.
Stratiﬁed by sex (Table 2), men had a higher BMI and a higher CCI
than women, however, these differences only approached statistical
signiﬁcance. Stratiﬁed by tertiles of total drug intake at baseline
(Table 3), mean age, BMI, CCI, and frequency of prevalent hypertension
and diabetes increased signiﬁcantly across drug intake tertiles,
whereas eGFR decreased signiﬁcantly.
Prospective Association Between Intake of Drugs and Kidney
Function
In the primary analysis (Table 1), over 24 months, with every
additional drug taken at baseline, kidney function declined by
0.64 mL/min/1.73 m2 eGFR in adjusted (Beta ¼ 0.64; P ¼ .024) and
unadjusted (Beta ¼ 2.37; P < .001) analysis. Also, with every
additional drug taken cumulatively over 24 months, kidney function
decreased by 0.39 mL/min/1.73 m2 eGFR in adjusted (Beta ¼ 0.39;
P ¼ .002) and unadjusted (Beta ¼ 0.84; P < .001) analysis (Table 1).
Subgroup Analysis on NSAID Intake and Kidney Function
Regarding the intake of NSAIDs (Table 1), there was no signiﬁcant
association between the number of NSAIDs at baseline and the decline
in kidney function over 24 months in adjusted (Beta ¼ 1.97; P ¼ .26)
and unadjusted (Beta ¼ 2.32; P ¼ .47) analysis. However, with every
additional NSAID taken cumulatively over 24 months, kidney function
declined by 1.21 mL/min/1.73 m2 eGFR in adjusted (Beta ¼ 1.21;
P ¼ .021) and nonsigniﬁcantly in unadjusted (Beta ¼ 1.25; P ¼ .09)
analysis (Table 1).
Sensitivity Analysis
When additionally adjusting the association between the baseline
or cumulative total number of drugs and kidney function for RAAS
blockers, over 24 months, higher baseline (Beta¼ 0.63; 95% CI1.20
to 0.06; P ¼ .030) or cumulative (Beta ¼ 0.38; 95% CI 0.62
to 0.14; P ¼ .002) intake of drugs was not associated with a signiﬁ-
cantly smaller decline of kidney function than without adjusting for
Table 2
Participant Characteristics by Sex
Men Women Sex Difference (P) Total Population
Participants, n (%) 126 (46.7) 144 (55.3) .25 270
Age, mean (SD), y 70.3 (6.9) 70.2 (6.0) .98 70.3 (6.4)
Body mass index, mean (SD), kg/m2 28.4 (4.7) 27.4 (4.3) .07 27.9 (4.5)
Prevalent hypertension, n (%) 64 (51.5) 58 (41.3) .09 122 (46.0)
Prevalent diabetes, n (%) 10 (7.9) 6 (4.2) .21 16 (6.0)
CCI (score 0e37), n (%) 0.6 (1.0) 0.4 (0.9) .06 0.5 (0.9)
<3 108 (85.7) 125 (89.9) .29 233 (87.9)
3 18 (14.3) 14 (10.1) 32 (12.1)
Intake of drugs (average number)
Total drugs
At baseline, mean (SD) 2.40 (2.18) 2.48 (1.89) .76 2.4 (2.0)
Cumulative at 24 mo, mean (SD) 14.80 (11.54) 14.52 (9.67) .84 14.7 (10.6)
NSAIDs, mean (SD)
At baseline, mean (SD) 0.14 (0.33) 0.19 (0.43) .35 0.17 (0.39)
Cumulative at 24 mo, mean (SD) 0.68 (1.21) 0.75 (1.47) .73 0.71 (1.35)
CKD-EPIcr-cys eGFR, mean (SD), mL/min/1.73 m2 81.9 (15.8) 81.4 (14.4) .78 81.6 (15.1)
Data (n ¼ 270 at baseline and n ¼ 226 at 24 mo) are crude means (SD) or n (%). Differences between men and women were assessed by using Student t test for continuous
variables and a c2 test for categorical variables. P values are 2-sided; statistical signiﬁcance was set at P < .05.
Table 3
Participant Characteristics by Tertiles of Total Drug Intake at Baseline
Tertile 1 (0‒1 Drugs) Tertile 2 (2‒3 Drugs) Tertile 3 (4‒10 Drugs) P or Ptrend
Participants, n (%) 101 (37.0) 102 (37.4) 70 (25.6) <.001
Female, n (%) 54 (37.5) 52 (35.1) 38 (26.4) .81
Age, mean (SD), y 69.1 (6.7) 70.3 (6.2) 71.8 (6.0) .008
Body mass index, mean (SD), kg/m2 27.2 (4.1) 27.8 (4.9) 29.0 (4.3) .020
Prevalent hypertension, n (%) 16 (16.3) 53 (53.0) 53 (79.1) <.001
Prevalent diabetes, n (%) 1 (1.0) 3 (3.0) 12 (17.7) <.001
CCI (score 0‒37), n (%) 0.32 (0.68) 0.37 (0.82) 0.97 (1.24) <.001
<3 90 (91.8) 92 (92.0) 51 (76.1) .003
3 8 (8.2) 8 (8.0) 16 (23.9)
Intake of drugs (average number)
Total drugs
At baseline, mean (SD) 0.54 (0.50) 2.47 (0.50) 5.21 (1.62) <.001
Cumulative at 24 mo, mean (SD)* 4.0 (2.8) 12.4 (2.0) 25.8 (8.4) <.001
NSAIDs, mean (SD)
At baseline, mean (SD) 0.06 (0.24) 0.22 (0.44) 0.25 (0.47) .006
Cumulative at 24 mo, mean (SD)* 0.29 (0.73) 0.80 (1.4) 1.0 (1.6) <.001
CKD-EPIcr-cys eGFR, mean (SD), mL/min/1.73 m2 85.4 (13.4) 80.7 (14.2) 77.4 (17.4) .0015
SD, standard deviation.
Data (n¼ 270 at baseline and n ¼ 226 at 24 mo) are crude means (SD) or n (%) for baseline tertiles of total drug intake (0e1 drugs, n ¼ 100; 2e3 drugs, n ¼ 102; 4e10 drugs,
n ¼ 68), Differences between tertiles of total drug intake at baseline were assessed by using a c2 test for categorical variables. For continuous variables, P for trend (Ptrend)
across tertiles of total drug intake at baseline was calculated from linear regression models using the median value of the individual tertiles as a continuous variable. P values
are 2-sided; statistical signiﬁcance was set at P < .05.
*Refers to 226 participants and cumulative tertiles of total drug intake at 24 mo (0e8 drugs, n ¼ 72; 9e17 drugs, n ¼ 71; 18e54 drugs, n ¼ 83).
R. Ernst et al. / JAMDA xxx (2019) 1e64
RAAS blockers. In summary, our results were independent of the in-
clusion or exclusion of RAAS blockers.
Discussion
In this prospective study observing 270 relatively healthy adults
aged 60 and older in 5 clinical visits over a 24-month follow-up, both a
higher total number of drugs at baseline and a higher cumulative
number of drugs over timewere associatedwith a signiﬁcantly greater
decline in kidney function. This association was independent of age,
sex, BMI, treatment groups of the original RCT, prevalence of diabetes,
prevalence of hypertension, and baseline kidney function, and further
adjustment for the CCI did also not change the results. Notably, among
this study sample of older adults with knee osteoarthritis, the cu-
mulative intake of NSAIDs was associated with an about 3 times
stronger decline in kidney function than the cumulative intake of an
average drug. To our knowledge, our study is the ﬁrst to prospectively
assess the association between cumulative intake of drugs and change
in kidney function over time among relatively healthy adults age
60 years and older.
Comparison with Other Studies
Consistent with our ﬁndings, a recent longitudinal study of
Bolmsjö et al17 in nursing home residents (mean age 85.0 years) found
that the number of drugs taken at baseline was an independent risk
factor for a decline in kidney function of >3 mL/min/1.73 m2 in 1 year.
This study, however, did not assess the cumulative intake of drugs
over time. Similarly, a recent cross-sectional study by König et al30
found that the prevalence of polypharmacy (deﬁned as 5 drugs
daily) was associated with an approximately 50% increased risk for
CKD in multivariable-adjusted analysis among adults with a mean age
of 68.7 years. Also, in line with these results, another cross-sectional
study of 1002 patients (mean age 63.5 years) reported an indepen-
dent association between polypharmacy (5 drugs daily) and CKD
risk (odds ratio 3.96).
Our subgroup analysis on regular NSAID intake revealed that a
higher cumulative number of NSAIDs was associated with a 3-fold
greater decline in kidney function over the 24-month follow-up
compared with the cumulative intake of an average drug. Acute kid-
ney injury due to NSAIDs is well established among older adults.12,13
The 3-times stronger association of the cumulative intake of NSAIDs
compared with an average drug in our study supports current
guidelines that most older adults are advised not to use NSAIDs for
pain control because of the increased cardiovascular, renal, and
gastrointestinal risk proﬁle.31
Putting our ﬁndings in a greater context of health effects among
older adults, polypharmacy has been linked to incidence of falls,32
fractures,32 delirium,33 cognitive impairment,34 and increased mor-
tality.35 In Switzerland, 3.3% of all hospitalizations are due to adverse
drug reactions and 8%e11% of hospitalized patients experienced a
relevant adverse drug reaction.36
This may in part be explained by drug-drug interactions, which
have been found to increase dramatically from 13% when taking 2
drugs up to 82% when taking 7 or more drugs.37 Moreover, older
adults are most vulnerable to drug-drug interactions because of
physiological changes that alter the pharmacokinetic and pharmaco-
dynamic with higher age.38 Further, it has been shown that clinicians
may misinterpret a drug adverse reaction as a newmedical condition,
leading to another drug prescription instead of withdrawing the
responsible drug.39
Notably, on the other hand, the withdrawal of speciﬁc classes of
drugs among older adults has been associated with a reduction in falls
and improvement in cognitive and psychomotor function when dis-
continuing psychotropic drugs and benzodiazepines.40 Moreover,
cessation of inappropriate antihypertensive agents has been associ-
ated with fewer cardiovascular events and deaths.41
Strengths and Weaknesses
Our study has several strengths. Most importantly, our study had a
prospective design with 5 repeated measurements over a 24-month
follow-up for both the high-quality standardized assessment of drug
intake and the complete instrument library to calculate the CKD-EPIcr-
cys eGFR. We chose the CKD-EPIcr-cys eGFR, as it has been shown to
provide the most exact eGFR for the age group of our study.7,2426
Further, we were able to adjust our analyses for important con-
founders such as age, sex, BMI, prevalence of diabetes, prevalence of
hypertension, the CCI, and the baseline value of the eGFR that are
known to impact kidney function.
Our study also has limitations. Importantly, although (1) the CCI
and incident comorbidities were rather low in our study population,
(2) we adjusted for possible confounders including important
comorbidities (ie, prevalences of hypertension and diabetes at base-
line, which are the most common causes of CKD among older
adults42), and (3) further adjustment for the CCI did not change our
result, we cannot rule out that residual confounding has biased our
results, in particular that the prevalence of comorbidities rather than
the drug treatment of the comorbidities has impacted the kidney
function over time. Moreover, the observational design of our study
and the moderate sample size per se do not allow for cause-effect
inference or generalization of our results, respectively. However, 5
repeated measurements reduced our measurement error, and the
study sample was large enough to investigate the subgroup of seniors
taking NSAIDs as a subgroup analysis for a high-risk medication
among older adults. Another limitation is that participants with an
eGFR <30 mL/min were excluded from the original RCT because of
safety reasons. Thus, our results can be considered conservative, as
individuals with severe kidney impairment were excluded. Another
possible limitation is that, at baseline, we were not able to include a
measure of prior kidney function or use of medications. To minimize
this concern, we adjusted our analyses for baseline eGFR.
Conclusions and Implications
Our ﬁndings show a clinically relevant negative and independent
association of polypharmacy with kidney function in relatively
healthy older adults. Although age alone may lead to a decline in eGFR
by about 0.8 to 1 mL/min/1.73 m2/year in adults over the age of
40,6,7,43,44 we demonstrated that among adults aged 60 and older,
eGFR may decline further and independently by 0.39 mL/min/1.73 m2
per drug over 2 years, and 3 times more if the drug is an NSAID
(1.21 mL/min/1.73 m2). Therefore, our study suggests that for kidney
health among adults aged 60 years and older, a careful risk-beneﬁt
evaluation for each prescribed drug may be warranted. However,
more research, including conﬁrmatory large-scale prospective cohort
studies on polypharmacy and kidney function, is needed to conﬁrm
our ﬁndings (ie, to better determine whether indeed the drug treat-
ment, rather than comorbid illnesses themselves, is responsible for
our ﬁndings).
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Supplementary Table 1
Disease and Frailty-Related Participant Information Over Time
Incident Diagnoses/Cases
Baseline 6 mo 12 mo 18 mo 24 mo
Baseline* and incidenty diagnoses
Hypertension [n (%)] 118 (43.7) 2 (0.7) 4 (1.6) 3 (1.1) 1 (0.4)
Diabetes [n (%)] 16 (5.9) 0 (0.0) 1 (0.4) 1 (0.4) 0 (0.0)
COPD [n (%)] 5 (1.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
CKD [n (%)] 7 (2.6) 3 (1.2) 2 (0.8) 1 (0.4) 0 (0.0)
Rheumatologic disease [n (%)]z 0 (0.0) n/a n/a n/a n/a
CVD [n (%)]x 30 (11.1) 3 (1.2) 4 (1.6) 2 (0.8) 3 (1.3)
Incident hospitalizationjj
Total [n (%)] n/a 25 (9.7) 44 (17.3) 41 (16.9) 32 (14.2)
Due to CVD [n (%)] n/a 5 (1.9) 6 (2.4) 6 (2.5) 7 (3.1)
Frailty criteria**
Weight loss [n (%)]yy n/a 12 (4.6) 22 (8.7) 21 (8.6) 20 (8.8)
Weakness [n (%)]zz 70 (25.9) 81 (31.3) 75 (29.5) 83 (34.2) 76 (33.6)
Exhaustion [n (%)]xx 7 (2.6) n/a 1 (0.4) n/a 2 (0.9)
Slowness [n (%)]jjjj 4 (1.5) 0 (0.0) 4 (1.6) 1 (0.4) 1 (0.4)
Low activity [n (%)]*** 85 (31.5) 84 (32.40) 84 (33.1) 84 (34.5) 84 (37.2)
Prevalence of frailty [n (%)]yyy n/a n/a 2 (0.8) n/a 1 (0.4)
AE, adverse event; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; n/a, not available due to missing information on single follow-ups, or in the case
of frailty because of missing information of single criteria needed to calculate the overall frailty score1; SAE, serious adverse event.
Data (n ¼ 270 at baseline [ie, 0 mo]; n ¼ 259 at 6 mo; n ¼ 254 at 12 mo; n ¼ 243 at 18 mo, n ¼ 226 at 24 mo) are n (%).
*Baseline diagnoses are based on case report ﬁle information at baseline.
yIncident diagnoses are based on AE reporting information over the 24-mo period.
zInﬂammatory arthritis including rheumatoid arthritis was an exclusion criterion of the original trial. Information on diagnosis of incident rheumatologic disease cases was
unfortunately unclear to deﬁne.
xCVD included myocardial infarction, peripheral cardiovascular disease, cerebrovascular insults, or transient ischemic attack.
jjAt baseline, all 270 patients can be considered “hospitalized” due to the unilateral knee replacement. Incident hospitalizations are based on SAE reporting information over
the 24-mo period (however, no information on acute intensive care was available). Over the 5 diagnoses considered, only incident CVD cases resulted in hospitalizations.
**Based on Fried et al.1
yyWeight loss was deﬁned as loss of >2.5 kg/6 mo by direct weight measurement based on Fried et al.1
zzWeakness was deﬁned by grip strength (measured with byMartin Vigorimeter) based on Fried et al.1 Cut-points for the weakness criterion at<64.3 kPa (approx.<32.1 kg)
for men and <42.7 kPa (approx. <2 kg) for women were used as an approximation of the lowest quintile approach by Fried et al1 and consistent with a report on optimal cut-
points of 20 kg (women) and 30 kg (men) for the diagnosis of sarcopenia.2
xxSimilar to Fried et al,1 exhaustion was operationalized as self-reported negative answer to the question “How often have you been full of energy during the last 4 wk?”
from the Short Form (36) Health Survey (SF-36) Questionnaire.3
jjjjSimilar to the original Fried et al1 conceptualization, slowness was deﬁned as a gait speed (walking time (s)/4 m) below a certain threshold by gender and height, (ie,
0.65 m/s (men 173 cm, women 159 cm) and 0.76 m/s (men >173 cm, women >159 cm).
***Low activity was deﬁned as performing less than 4000 steps per day, equaling the average daily amount of steps of most people perform per day.4
yyyPrevalence of frailty was calculated based on the overall frailty score of Fried et al.1
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Supplementary Fig. 1. Total number of drug intake at baseline and kidney function at
baseline. Data (n ¼ 270) are the total number of drugs (SD) taken at baseline cate-
gorized by the KDIGO (Kidney Disease: Improving Global Outcomes) classiﬁcation
according to the creatinine and cystatin-based CKD-EPIcr-cys estimated glomerular
ﬁltration rate eGFR at baseline. Participants in the G1 (eGFR > 90, mean eGFR ¼ 97.9),
G2 (eGFR 60e89, mean eGFR ¼ 77.7), G3a (eGFR 45e59, mean eGFR ¼ 54.7), and G4b
(eGFR 30e44, mean eGFR ¼ 41.0) category had a mean intake of 1.92 (n ¼ 83), 2.48
(n ¼ 163), 3.80 (n ¼ 19), and 4.80 (n ¼ 5) drugs, respectively.
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